Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 1;13:868915. doi: 10.3389/fimmu.2022.868915

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Milo, Staun-Ram, Karussis, Karni, Hellmann, Bar-Haim, Miller and The Israeli Neuroimmunology Study Group on COVID-19 Vaccination in Multiple Sclerosis

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

(A) Mean IgG levels after 2^nd vaccine in patients with < (white) or ≥ (black) 1-6 months between last Ocrelizumab infusion and 1^st vaccine. (B) Mean IgG levels after 3^rd vaccine in patients with < (white) or ≥ (black) 1-6 months between last Ocrelizumab infusion and 3^rd vaccine. (C) IgG levels of Ocrelizumab-treated patients at 3 time-points: ≤3months and 6 months from 2^nd vaccine and ≤3 months from 3^rd vaccine. (D) Comparison of IgG levels in Ocrelizumab-treated patients at 3 time-points: ≤3months (N=89) and 6 months (N=38) from 2^nd vaccine and ≤3 months from 3^rd vaccine (N=43). Dashed horizontal grey line represents minimum seropositive border (log10(50AU/ml).